Published in

Elsevier, Biology of Blood and Marrow Transplantation, 5(20), p. 690-695, 2014

DOI: 10.1016/j.bbmt.2014.01.027

Links

Tools

Export citation

Search in Google Scholar

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute Myeloid Leukemia

Journal article published in 2014 by Robert J. Guo, Eshetu G. Atenafu ORCID, Ken Craddock, Hong Chang
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Monosomal karyotype (MK) and complex karyotype (CK) are well known to be associated with a very poor clinical outcome in patients with acute myeloid leukemia (AML). However, whether or not the prognostic impact of MK and CK remains relevant for patients who have undergone allogeneic hematopoietic cell transplant (allo-HCT) is still unclear. We retrospectively analyzed the status of MK and CK, as well as other clinical laboratory features, in 148 allo-HCT AML patients at our institution and correlated with their event-free survival (EFS) and overall survival (OS) after transplantation. MK and CK were identified in 14 (9%) and 19 (13%) cases, respectively. On univariate analysis, only age (≥ 60 years) and WBC count (≥ 15 x 10(9) per litre) were significant adverse predictors for EFS (P < 0.001 and P = 0.017, respectively) and OS (P = 0.002 and P = 0.021, respectively). MK, CK, and other relevant parameters analyzed did not affect the clinical outcome. Multivariable analysis confirmed that both older age and high WBC count were independent prognostic factors for a shorter OS (P = 0.001 and P = 0.003, respectively) and a shorter EFS (P < 0.001 and P = 0.001, respectively). Our results indicate that neither MK nor CK are high risk factors in AML patients undergoing allo-HCT, while both are significant in AML patients who did not receive allo-HCT.